NVUS Novus Therapeutics Inc.

1
+0.02  (+2%)
Previous Close 0.98
Open 0.98
Price To Book 1.3
Market Cap 12,896,473
Shares 12,896,473
Volume 124,138
Short Ratio
Av. Daily Volume 227,722

NewsSee all news

  1. Novus Therapeutics to Present OP0201 Data at the 20th International Symposium on Recent Advances in Otitis Media
  2. Novus Therapeutics Reports First Quarter 2019 Financial Results
  3. Novus Therapeutics Announces Closing of $10.7 Million Registered Direct Offering Priced At-the-Market
  4. Novus Therapeutics Announces $10.7 Million Registered Direct Offering Priced At-the-Market
  5. Novus Therapeutics Announces Results of Two Single-Dose OP0201 Phase 1 Clinical Trials

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial discontinued July 2016 due to poor data
Galeterone - ARMOR3-SV
Cancer - castration-resistant prostate cancer (CRPC)
Announced in August 2016 that Phase 2 trial enrollment has been discontinued.
Galeterone - ARMOR2
Xtandi (enzalutamide) refractory metastatic castration-resistant prostate cancer (mCRPC)
Phase 1 data presented June 11, 2019, 1pm.
OP0201- C-002
Healthy volunteers
Phase 1 data released April 22, 2019. Safety and tolearbility objectives met.
OP0201 C-001
Healthy volunteers
Phase 1 data released April 22, 2019. Safety and tolerability objectives met.
OP0201
Acute Otitis Media - adults
Phase 2a data due 1H 2020.
OP0201 - C-006
Acute Otitis Media - children
Phase 1 data released April 22, 2019. Safety and tolerability objectives met.
OP0201 - C-001
Healthy volunteers

Latest News

  1. Novus Therapeutics to Present OP0201 Data at the 20th International Symposium on Recent Advances in Otitis Media
  2. Novus Therapeutics Reports First Quarter 2019 Financial Results
  3. Novus Therapeutics Announces Closing of $10.7 Million Registered Direct Offering Priced At-the-Market
  4. Novus Therapeutics Announces $10.7 Million Registered Direct Offering Priced At-the-Market
  5. Novus Therapeutics Announces Results of Two Single-Dose OP0201 Phase 1 Clinical Trials
  6. Novus Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Clinical Updates
  7. Novus Therapeutics to Participate in the 8th Annual SVB Leerink Global Healthcare Conference
  8. Novus Therapeutics Doses First Patients in Phase 2a Trial of OP0201
  9. Company Profile for Novus Therapeutics, Inc.
  10. Novus Therapeutics Doses First Subjects in Phase 1 Pharmacodynamics Study of OP0201
  11. Novus Therapeutics Advances OP0201 Development Program Across Several Clinical Trials
  12. Novus Therapeutics Doses First Patient with Acute Otitis Media in Phase 1 Study of OP0201
  13. Can We See Significant Institutional Ownership On The Novus Therapeutics, Inc. (NASDAQ:NVUS) Share Register?
  14. Novus Therapeutics Announces Formation of Scientific Advisory Board
  15. Novus Therapeutics Doses First Subjects in Phase 1 Study of OP0201
  16. Novus Therapeutics to Present at the 2018 Piper Jaffray Healthcare Conference
  17. Novus Therapeutics Reports Third Quarter 2018 Financial Results
  18. Novus Therapeutics to Present at the Ladenburg Thalmann 2018 Healthcare Conference
  19. Novus Therapeutics to Postpone Offering of Common Stock
  20. Novus Therapeutics Announces Proposed Public Offering of Common Stock